Leukemia Research
Investigating molecular drivers, clonal evolution, measurable disease, treatment response, and mechanisms of resistance across acute and chronic leukemias.

Our research portfolio moves across discovery biology, disease-specific investigation, translational science, biomarkers, precision medicine, and cancer control.
Blood cancers offer a powerful setting for studying cancer biology, immune interactions, clonal evolution, treatment resistance, and measurable disease response.
Investigating molecular drivers, clonal evolution, measurable disease, treatment response, and mechanisms of resistance across acute and chronic leukemias.
Studying lymphoma biology, tumor-immune interactions, molecular subtypes, biomarkers, and therapeutic strategies.
Researching disease progression, marrow biology, treatment resistance, and approaches to durable disease control.
Investigating malignant and pre-malignant hematologic conditions and the biological pathways that connect disease states.
Characterizing genomic alterations and molecular signatures associated with disease biology and treatment response.
Exploring immune-cell function, cellular therapies, and mechanisms that influence anti-cancer activity.
Developing measurable indicators that can improve classification, monitoring, and response-guided research.
Understanding how surrounding cells, signals, and tissue architecture influence cancer behavior.
Studying why cancers adapt to treatment and identifying research opportunities to overcome resistance.
Examining risk, screening, early detection, survivorship, and strategies that reduce cancer burden.